Latest News and Press Releases

BPGbio highlights groundbreaking data on BPM31510 illustrating it's therapeutic impact as a potential treatment for primary CoQ10 deficiency.

The first patient has been dosed in Tisento's global Phase 2b PRIZM study investigating zagociguat in MELAS.

21 November 2024 – The United Mitochondrial Disease Foundation’s (UMDF) venture philanthropy arm, The Mito Fund, has invested in Khondrion, a Netherlands-based clinical stage biopharmaceutical company...

Interim data confirms OMT-28’s strong safety profile in PMD patients, top-line data expected mid-2025 BERLIN, GERMANY, September 26, 2024 – OMEICOS, a biopharmaceutical company developing...

Khondrion appoints Jasper Levink as Chief Financial and Business Officer NIJMEGEN, the Netherlands – 11 September 2024: Khondrion, a clinical stage biopharmaceutical company discovering and...

CAMBRIDGE, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) today announced that the Board of Directors of the Company acting solely by all of its independent and...

Recent positive MELAS clinical study data drive urgency to deliver potential first-ever therapy for patients with rare, genetic mitochondrial diseases Development programs prioritized and...

Positive topline results for CY6463 announced in two clinical studies in patients with Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like episodes (MELAS) and Cognitive Impairment...

Data for CY6463, a first-in-class, CNS-penetrant, sGC stimulator, demonstrate safety and positive effects across biomarkers of disease in MELAS patients Company leadership discussed key insights for...

Company to discuss positive topline and additional clinical data for CY6463 in MELAS patients Mitochondrial disease clinician-researcher, Amel Karaa, M.D., to discuss the potential future impact on...